Overview

Vaginal Progesterone to Reduce the Risk of Another Preterm Birth

Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
This research study is being conducted at over 12 pregnancy research centers in the US. The study will compare an investigational treatment with a placebo (a treatment without medication). Neither the investigators nor the patients in the trial will know which treatment has been assigned. All study medications will be given vaginally once a day. Treatment will begin before pregnancy week 23 and will continue until the end of pregnancy week 36.
Phase:
Phase 3
Details
Lead Sponsor:
Juniper Pharmaceuticals, Inc.
Treatments:
Progesterone